blood testpharmacologic approaches to glycemic treatment
blood test: Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.
pharmacologic approaches to glycemic treatment: documenting the change of glycemic treatment during the follow-up period
Study summary
To explore the risk factors influencing glycemic status, optimized treatment, and prognosis of post-chronic pancreatitis diabetes mellitus (PPDM-C).
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. patients with diagnosis of chronic pancreatitis and diabetes mellitus.
2. participants with painless chronic pancreatitis were diagnosed with diabetes within 2 years of the diagnosis of chronic pancreatitis.
3. participants with painful chronic pancreatitis were diagnosed with diabetes after the first attack of chronic pancreatitis.
Exclusion Criteria:
1. participants with suspected malignant tumors of the pancreas or other sites of body, or participants in the terminal stage of severe disease
2. serious mental illness, lesion of liver or kidney, pregnancy, breast-feeding or planning pregnancy
3. definitely diagnosed type 1 diabetes, type 2 diabetes, or other metabolic diseases that affect blood glucose
4. autoimmune pancreatitis
5. Scarcity of information related to HbA1c
6. death or loss of follow-up during follow-up
Primary outcome measure(s)
Hemoglobin A1c (HbA1c) — through study completion, an average of 1 year measure the control of blood glucose of every 3 months
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.